All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2023-09-05T09:54:04.000Z

5-year follow-up trial of nivolumab in R/R classical Hodgkin lymphoma: CheckMate 205

Sep 5, 2023
Share:
Learning objective: After reading this article, learners will be able to describe the long-term outcomes of nivolumab in R/R cHL.

Bookmark this article

Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.

Patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) have a poor prognosis after an initial treatment with autologous hematopoietic stem cell transplant (auto-HSCT) with an overall survival (OS) of approximately 2 years. Initial data from the CheckMate 205 (NCT02181738) trial demonstrated good efficacy and safety with nivolumab after auto-HSCT. The Lymphoma Hub has previously summarized 2-year follow-up data from the CheckMate 205 trial. Below, we present the extended 5-year follow-up data to understand long-term outcomes after nivolumab administration.

Study design

This is a phase II trial of nivolumab in patients with R/R cHL who had failed previous treatment with auto-HSCT. Full details of the study design are previously summarized on the Lymphoma Hub. Eligible patients were:

  • aged 18 years;
  • diagnosed with cHL and failed treatment with auto-HSCT;
  • grouped according to prior treatment with brentuximab vedotin (BV): BV naïve (cohort A), received BV after auto-HSCT failure (cohort B) or received BV before/after auto-HSCT (cohort C).

The primary endpoint was the objective response rate. Secondary endpoints included duration of response, complete remission (CR), partial remission rate and duration of CR and partial remission. Exploratory endpoints included progression-free survival, best overall response  OS, and safety.

Results

Efficacy

In total, 243 patients were treated in cohort A (n = 63), cohort B (n = 80) and cohort C (n = 100). At a median follow-up of 58.5 months:

  • A total of 58 patients received subsequent allogeneic HSCT, with the highest proportion of patients in cohort C (Table 1).
  • Median OS was not reached in any cohort.
  • The 2-year OS rate was 87.1% (95% CI, 82–90.8) and the 5-year OS rate was 71.4% (95% CI, 64.8–77.1).

Table 1. Responses between cohorts A, B and C.*

Response, % (unless otherwise stated)

Cohort A (BV-naive)

(n = 63)

Cohort B (BV after auto-HSCT)

(n = 80)

Cohort C (BV before and/or after auto-HSCT)

(n = 100)

Overall

(N=243)

 

ORR

65.1

71.3

71.2

71.2

BOR

CR

31.7

13.8

21

21.4

PR

33.3

57.5

54

49.8

SD

22.2

17.5

12

16.5

PD

12.7

8.8

11

10.7

Median time to response, months

2.0

2.2

2.1

2.1

Median time to CR, months

3.9

4.4

4.2

4.0

Median DoR, months

26.2

16.6

18.2

18.2

Received subsequent allogeneic HCT

22.4

24.1

51.7

23.9

Auto-HSCT, autologous stem hematopoietic cell transplantation; BOR, best overall response; BV, brentuximab vedotin; CR, complete remission; DoR, duration of response; ORR, objective response rate; PD, progressive disease; PR, partial remission; SD, stable disease. 

*Adapted from Ansell SM, et al.1

Safety

  • Treatment related adverse events (TRAEs) occurred in 81.5% of patients and 27.6% were classed as Grade 3–4.
  • The most common TRAEs (occurring in 10% patients) were fatigue, diarrhea, infusion-related reaction, rash, nausea, pruritus (Figure 1).
  • In total, 22 patients discontinued treatment due to TRAEs and 13 patients due to Grade 3–4 TRAEs, with pneumonitis being the most common adverse event leading to discontinuation (2.9%).
  • There were no deaths reported.

Figure 1. The most common (10% occurrence in patients) TRAEs reported*

 

TRAEs, treatment related adverse events.
*Adapted from Ansell SM, et al.1

Conclusion

The 5-year follow-up data from CheckMate 205 trial are consistent with the previously reported 18 and 33 months results. Nivolumab showed durable outcomes in patients with cHL who were R/R after auto-HSCT, and no new safety signals were identified. This study also provides evidence that patients may discontinue treatment one year after CR and restart treatment if cHL progresses. 

  1. Ansell SM, Bröckelmann PJ, von Keudell G, et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from pivotal phase 2 CheckMate 205 study. Blood Adv 2023;1-28. DOI: 10.1182/bloodadvances.2023010334

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
60 votes - 46 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox